293 related articles for article (PubMed ID: 24490159)
1. Novel strategies for the treatment of chondrosarcomas: targeting integrins.
Chen JC; Fong YC; Tang CH
Biomed Res Int; 2013; 2013():396839. PubMed ID: 24490159
[TBL] [Abstract][Full Text] [Related]
2. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Cleton-Jansen AM; van Beerendonk HM; Baelde HJ; Bovée JV; Karperien M; Hogendoorn PC
Clin Cancer Res; 2005 Nov; 11(22):8028-35. PubMed ID: 16299232
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in chondrosarcomas - keys to targeted therapies?
Samuel AM; Costa J; Lindskog DM
Cell Oncol (Dordr); 2014 Apr; 37(2):95-105. PubMed ID: 24458248
[TBL] [Abstract][Full Text] [Related]
4. Update on chondrosarcomas.
Chow WA
Curr Opin Oncol; 2007 Jul; 19(4):371-6. PubMed ID: 17545802
[TBL] [Abstract][Full Text] [Related]
5. Chondrosarcoma: biology, genetics, and epigenetics.
Chow WA
F1000Res; 2018; 7():. PubMed ID: 30519452
[TBL] [Abstract][Full Text] [Related]
6. A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression.
Kim H; Cho Y; Kim HS; Kang D; Cheon D; Kim YJ; Chang MJ; Lee KM; Chang CB; Kang SB; Kang HG; Kim JH
Nat Commun; 2020 Oct; 11(1):5023. PubMed ID: 33024108
[TBL] [Abstract][Full Text] [Related]
7. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
8. [Inflammation as molecular target in chondrosarcoma].
Kalinski T
Pathologe; 2014 Nov; 35 Suppl 2():249-53. PubMed ID: 25394974
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetics as a tool in the histologic subclassification of chondrosarcomas.
Dijkhuizen T; van den Berg E; Molenaar WM; Oosterhuis JW; Dam A; Wiersema J; Schraffordt Koops H; de Jong B
Cancer Genet Cytogenet; 1994 Sep; 76(2):100-5. PubMed ID: 7923056
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of human chondrosarcomas for matrix production and cancer markers.
Söderström M; Böhling T; Ekfors T; Nelimarkka L; Aro HT; Vuorio E
Int J Cancer; 2002 Jul; 100(2):144-51. PubMed ID: 12115562
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.
Higuchi T; Takeuchi A; Munesue S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Inatani H; Shimozaki S; Kato T; Aoki Y; Abe K; Taniguchi Y; Aiba H; Murakami H; Harashima A; Yamamoto Y; Tsuchiya H
Cancer Med; 2018 May; 7(5):1944-1954. PubMed ID: 29573200
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
13. The clinical management of chondrosarcoma.
Riedel RF; Larrier N; Dodd L; Kirsch D; Martinez S; Brigman BE
Curr Treat Options Oncol; 2009 Apr; 10(1-2):94-106. PubMed ID: 19238552
[TBL] [Abstract][Full Text] [Related]
14. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Speetjens FM; de Jong Y; Gelderblom H; Bovée JV
Curr Opin Oncol; 2016 Jul; 28(4):314-22. PubMed ID: 27166664
[TBL] [Abstract][Full Text] [Related]
15. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Nazeri E; Gouran Savadkoohi M; Majidzadeh-A K; Esmaeili R
Crit Rev Oncol Hematol; 2018 Nov; 131():102-109. PubMed ID: 30293700
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic molecular targets in human chondrosarcoma.
Jamil N; Howie S; Salter DM
Int J Exp Pathol; 2010 Oct; 91(5):387-93. PubMed ID: 21078112
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR.
Zhu Z; Wang CP; Zhang YF; Nie L
Asian Pac J Cancer Prev; 2014; 15(2):917-23. PubMed ID: 24568519
[TBL] [Abstract][Full Text] [Related]
18. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
Rozeman LB; Hameetman L; van Wezel T; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
J Pathol; 2005 Sep; 207(1):61-71. PubMed ID: 16007578
[TBL] [Abstract][Full Text] [Related]
19. Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Hung SY; Lin CY; Yu CC; Chen HT; Lien MY; Huang YW; Fong YC; Liu JF; Wang SW; Chen WC; Tang CH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445345
[TBL] [Abstract][Full Text] [Related]
20. Decoupling NAD
Suh J; Kim H; Min J; Yeon HJ; Hemberg M; Scimeca L; Wu MR; Kang HG; Kim YJ; Kim JH
Cell Rep Med; 2024 Jan; 5(1):101342. PubMed ID: 38128534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
